A phase III study of Fluorine-18-MK-6240

Trial Profile

A phase III study of Fluorine-18-MK-6240

Planning
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Fluorine-18-MK 6240 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 10 Jan 2017 New trial record
    • 05 Jan 2017 According to a Cerveau Technologies media release, the company plans to initiate this study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top